Mark T Reding MD
Assistant Professor, Medicine, University of Minnesota Medical School
Overview of Dr. Reding
Dr. Mark Reding is an oncologist in Minneapolis, MN. He received his medical degree from University of Minnesota Medical School and has been in practice 33 years. He has more than 60 publications and over 500 citings.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1996 - 1999- University of MinnesotaResidency, Internal Medicine, 1992 - 1995
- University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
MN State Medical License 1994 - 2025
Publications & Presentations
PubMed
- Recombinant factor VIIa: new insights into the mechanism of action through product innovation.Miguel A Escobar, Maureane Hoffman, Giancarlo Castaman, Cedric Hermans, Johnny Mahlangu
Research and Practice in Thrombosis and Haemostasis. 2025-01-01 - Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez
Acta Haematologica. 2025-01-01 - Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore
Drugs in R&D. 2024-12-20
Press Mentions
Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual SummitJune 15th, 2020
FDA Approves JiviAugust 31st, 2018
